Wockhardt Limited has informed the Exchange about Transcript
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Wockhardt filed the transcript of its investor conference where management reviewed FY25 results and outlined growth plans. The company reported FY25 revenue of INR 3,033 crores, with EBITDA of INR 418 crores — a 67% jump driven by a 500 bps margin expansion (9% to 14%). Net debt fell sharply from INR 882 crores in FY22 to INR 64 crores in FY25, and the company is sitting on ~INR 600 crores of cash after a INR 1,000 crore QIP. Key antibiotic ZAYNICH completed global Phase 3 trials with 20% superiority, has filed with DCGI, and the company plans a USFDA filing soon with US launch targeted by mid next year; global addressable market is pegged at ~$9 billion. Miqnaf, a new macrolide antibiotic, was launched in India on May 27, 2025, with an India TAM of INR 10,800 crores. The diabetes/biosimilar business (Insulin Glargine, Aspart) is being scaled, with capacity doubling planned over 24–36 months to tap a ~$3 billion emerging market opportunity.
Positive for sentiment: strong margin expansion, near-zero net debt, and clear visibility on high-value novel antibiotic launches in the US and India over the next 12–18 months. Investors should watch USFDA filing progress for ZAYNICH and India launch ramp-up, as these are the key value drivers management has highlighted.